THERAPY OF METABOLIC SYNDROME AND AGE-RELATED HYPOGONADISM OF MEN
DOI:
https://doi.org/10.54890/1694-6405_2023_3_55Abstract
Complex therapy was performed on patients with androgen deficiency in combination with various manifestations of metabolic syndrome. The group of patients who received the treatment with testosterone tablets represented positive results in the clinical manifestations of metabolic disorders. The main manifestation of the positive dynamics of treatment is the normalization of the level of total and free Testosterone (up to 12.8 nmol / l, up to 256.9 pmol / l) (p>0.05). Also, there was a significant decrease in body weight from 109 kg to 97 kg. Glycolized hemoglobin dropped from 5.6% to 3.6%. Globulin-binding sex hormone levels have normalized to 30.6 nmol/l. There was a statistically significant decrease in cholesterol to 3.8 mmol/l, low-density lipoproteins to 3.6 mmol/l, the atherogenicity index to 3.4. The ICEF and IPSS questionnaire indicators improved. Received data confirm the need to correct androgen deficiency in the treatment of metabolic syndrome in men, since with the normalization of the level of total and free testosterone in the blood, there is a clinically significant normalization of metabolic disorders.
Keywords:
androgen deficiency, metabolic syndrome, Testosterone preparations, erectile dysfunction, BPH, body weight change, glycolized hemoglobin, globulin-binding sex hormone, cholesterol, low-density lipoproteins, index atherogenicity, ICEF and IPSS questionnaire.References
1. Аляев Ю.Г., Григорян В.А., Пронин В.С., Соколдова О.В., Чалый М.Е. Возрастной андрогенный дефицит и современные методы его медикаментозной коррекции. Врачебное сословие. 2006;5-6:50-53.
2. Калинченко С.Ю., Вадов В., Ворслов Л. Возрастной дефицит андрогенов у мужчин: диагностика и лечение. Врач. 2008;6:21-24.
3. Богданов А.Б., Велиев Е.И. Современные возможности терапии андрогенного дефицита у мужчин: методические рекомендации для практического врача. М.: РМАПО; 2009:33-35.
4. Бакыт Ж.К. Комбинированная заместительная гормонотерапия эректильной дисфункции при возрастном гипогонадизме в комплексе с инфибитором ФДЭ – 5 типа. Вестник МЦ УДП РК. 2009;4(33):118 – 123.
5. Дедов И.И. Возрастной андрогенный дефицит. Практическая медицина, 2016. 239 с.
6. Жиенбаев Е.Р., Абдикадыр Ж.Н., Жанкина Р.А., Ахметов Д.Э. Доброкачественная гиперплазия предстательной железы и возрастной гипогонадизм у пациентов с метаболическим синдромом. Астана медициналык журналы. 2018;1:9.
7. Хайрли Г.З., Бакыт Ж.К., Жиенбаев Е.Р. Возрастной андрогенный дефицит. Учебно-методическое пособие. Астана. 2014. 123 с.
8. Жанкина Р.А. Прогнозирование клинического течения метаболического синдрома у мужчин с возрастным гипогонадизмом. Астана. 2018. 85 с.
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21): 2709-2716. https://doi.org/10.1001/jama.288.21.2709
10. Malik S, Wong ND, Franklin SS. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adult. Circulation. 2004;110(10):1245-1250. https://doi.org/10.1161/01.CIR.0000140677.20606.0E
11. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardivascular morbidity associated with the metabolic syndrome. Diabetes Care. 2001;24 (4):683-689.
12. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern.Med. 2004;164(10):1066-1076. https://doi.org/10.1001/archinte.164.10.1066
13. Startberg J, von Mühlen D, Sundsfjord J, Jorde R. Walst circumference and testosterone levels in community dwelling men. The Tromsi study//Europ. J. Epidemiol. 2004;19(7):657-663. https://doi.org/10.1023/b:ejep.0000036809.30558.8f
14. Marin P., Arver S. Androgens and abdominal obesity. Bailliere”s Clin. Endocrinol. Metab. 1998;12(3):441-451.
15. Trai EC, Boyko EJ, Leonetti DL, Fujimoto WY. Low serum testosterone level as predictor of increased visceral fat in Japanese-American men. Int J. Obes. Relat. Metab. Disort., 2000;24:485-491.
Downloads
Published
How to Cite
Issue
Section
